Joseph Romanelli
Vermögen: 4 Mio $ am 30.09.2026
Vermögen: 4 Mio $ am 30.09.2026
Joseph Romanelli is currently President, Chief Executive Officer & Director at Tessera Therapeutics, Inc. since 2026.
Mr. Romanelli is Chief Executive Officer & Partner at Flagship Pioneering, LLC starting in 2026.
Mr. Romanelli serves as an Independent Director at Kimberly-Clark Corp.
beginning in 2024.
Former roles include Chief Executive Officer at CORXEL Pharmaceuticals (Shanghai) Co., Ltd. from 2021 to 2022.
Mr. Romanelli was Head-Investor Relations at Merck & Co., Inc. from 1996 to 2015.
Mr. Romanelli held the position of Head-Investor Relations at Schering-Plough Corp.
USA. Mr. Romanelli was President-Human Health International at Merck & Co., Inc. Education includes an undergraduate degree from the University of Delaware and an MBA from Gabelli School of Business.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.01.2026 | 28 739 ( 0 % ) | 4 Mio $ | 30.09.2026 | |
| 02.01.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KIMBERLY-CLARK CORPORATION | Direktor/Vorstandsmitglied | 13.11.2024 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that writes therapeutic messages into the genome to treat diseases | Vorstandsvorsitzender | 23.07.2026 |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Vorstandsvorsitzender | 01.01.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd.
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd. BiotechnologyHealth Technology Develops and commercializes novel therapeutics for cardiometabolic diseases | Vorstandsvorsitzender | 01.07.2022 |
| MERCK & CO., INC. | Investor Relations Kontakt | 01.07.2015 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Public Communications Contact | 04.11.2009 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 8 |
|---|---|
Kimberly-Clark Corp.
Kimberly-Clark Corp. Household/Personal CareConsumer Non-Durables Manufactures paper based products and provides cleaning solutions | Consumer Non-Durables |
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
University of Delaware
University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gabelli School of Business
Gabelli School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that writes therapeutic messages into the genome to treat diseases | Health Technology |
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd.
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd. BiotechnologyHealth Technology Develops and commercializes novel therapeutics for cardiometabolic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen